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ABSTRACT 
 
Therapy-resistance and relapse remain problematic in many cancer patients, 
despite the advancement in anti-cancer therapies. There is a constant need of 
developing new anti-cancer drugs to combat tumors keeping in mind also the 
increasing incidence rate of cancers as well as the incidences of relapse. 
Successful development of new drugs strongly depends on the predictability 
of the employed preclinical model. Currently used animal models (mostly 
xenografts and to some extent also gene modified animals) have resulted in 
progress but still experience some limitations. Many anti-cancer drugs have 
shown to be working in preclinical models, but proved ineffective in patients. 
It is therefore very important to develop better pre-clinical models providing 
and improving clinically relevant predictions should be developed. This study 
was carried out to test a novel pre-clinical model originally suggested by 
Tzukerman et al. 2003, using pluripotent stem cell induced teratoma (PSCT). 
For characterization of this experimental microenvironment, early and late 
events were studied in PSCT generated from the embryonic stem cell line 
HS181. Paper I demonstrated the occurrence of a benign embryonic process 
including increasingly chaotic embryonic tissues. An emerging organoid 
development was observed exhibiting cellular differentiation with close 
resemblance to that of the developing human embryo. Presence of also neural 
areas with prolonged immaturity was frequently observed, and with a 
morphology similar to that appearing in malignant tumors.  
 
We hypothesized from this that areas of immature neural condensation in 
PSCT may provide a growth supporting neoplastic niche for neuroectodermal 
tumors. The findings in paper II and III suggested that the microenvironment 
in PSCT provide adequate support for growth of neuroectodermal tumors, 
preferably of childhood origin. To test for clinical relevance of these findings, 
we next evaluated the PSCT for in situ growth and progression of fresh or 
frozen/thawed tumor biopsy materials obtained from the surgery of childhood 
tumor patients at the Karolinska University Hospital. Sections from the PSCT 
model demonstrated unique in vivo capturing of progression and micro 
invasion of the transplanted patient primary tumors - with striking similarities 
to the tumor conditions in the young patient. Further, an engraftment tropism 
was observed for implanted tumor cell lines, as well as for patient tumor 
specimens. In particular, a Neuroblastoma and a Supratentorial primitive 
neuroectodermal tumor revealed a clear tropism for engraftment in that the 
Neuroblastoma exclusively incorporated into looses mesenchyme and the 
Supratentorial primitive neuroectodermal tumor into condensing neural 
ectoderm. In conclusion, we have demonstrated that PSCT delivers an in vivo 
environment allowing childhood neuroectodermal tumors to maintain most of 
their original characteristics from the patient. This suggest that the PSCT 
environment is especially well suited for the assessment, and a strong 
complementary pre-clinical model for in vivo studies of these tumors. 
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1 INTRODUCTION  
 
The research in this thesis includes both experimental and translational angles, where 
the focus is on studies of neuroectodermal tumors, specifically neuroblastoma (NB), 
primitive neuro-ectodermal tumor (PNET) and melanoma. Like most other tumors, 
these tumors are extremely complex, and can be very heterogeneous with regard to 
their clinical outcome, where some tumors are more benign, while others are more 
aggressive and have an extremely poor outcome.  
 
Studies of tumors can be done in their natural host, in vitro by establishing the tumor 
cells as cell lines or in vivo by growing the tumors in different animal models.  
To distinguish these tumors more readily and to be able to later possibly study their 
response to different therapies, we need better in vivo models. Previous models using 
cell lines in vitro, as well as xenografting in vivo have had their limitations and to study 
new models enabling a more differentiated observation of the different cells in a tumor 
would be of great value.  
 
In this thesis I have studied the use of a novel species-specific in vivo model in 
comparison with traditional xenografts in different ways. However, before diving in 
more detail into this very specific area a more general introduction of some aspects of 
this thesis is presented below.  
 
1.1 CANCER 
Cancer is a general name (meaning “crab” in Latin and Greek) given to a group of 
diseases, which are characterized by the uncontrolled cell division, growth and spread 
and where the spread of the disease destroys its adjacent environment. It is a leading 
cause of death worldwide. Despite the advancement in the early detection methods and 
improved therapies, cancer still remains a great challenge for today’s health care 
system. According to a recent report, incidence of cancer worldwide is predicted to 
increase from 12.7 million cases in 2008 to 22.2 million by 2030 (up to 75%) with a 
predicted increase in cancer-related deaths up to 13.2 million in 2030 from 7.6 million 
in 2008 (Bray et al., 2012; Ferlay et al., 2010). 
 
Under normal circumstances, every cell in the body is orderly controlled by the 
mechanisms that determine when a cell should divide and when it should die. When a 
group of cells have lost their ability to respond to these homeostasis mechanisms, 
resulting in an uncontrolled growth of unwanted cells, a cancer may arise. The cells in 
this cancer may also be capable of invading and metastasizing to tissues far from the 
organ where the cancer originally started, a characteristic which most of the advanced 
tumors possess and is a major cause of cancer-related deaths. 
 
Acquisition of tumorigenecity in normal cells is a multi-step process as described e.g. 
by Hanahan et al (Hanahan and Weinberg, 2000, 2011). During cell division the 
information coded in the DNA of a cell is transferred to the daughter cells under strict 
control. Any mutation in the DNA is normally cleared by the DNA repair mechanism 
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and/or the affected cell is killed by body’s immune system. In cases where mutations 
escape these control mechanisms, these mutations continue to persist/stay in the 
progeny cells. If these mutations occur in the genes controlling DNA repair machinery, 
it is expected that the cellular progenies will accumulate multiple mutations due to a 
lack of efficient repair mechanism. This multi-step acquisition of tumorigenecity may 
in some cases lead to cancer development.  
 
Cancer cells acquire certain characteristics in order to sustain their growth and to 
escape different anti-tumor mechanisms – and these characteristics are described as 
Hallmarks of cancer by Hanahan (Hanahan and Weinberg, 2000, 2011) and illustrated 
in Fig. 1. 
 
 
 
 
Figure 1: A drawing showing the hallmarks of cancer: Adapted from Hanahan et al, 2010, reproduced 
with permission from http://www.gettingtoknowcancer.org/overview.php 
 
More specifically Hanahan describes how mechanisms such as, self-sufficiency in 
growth signals, insensitivity to anti-growth signal, invasion and metastasis to 
neighboring tissues, limitless replicative potential, sustained angiogenesis and 
mechanisms to evade apoptosis can be involved in cancer development. Not all 
mechanisms are involved in all cancers, and in some cancers some mechanisms are 
more prominent than others. 
 
In this thesis, the focus is on childhood neurectodermal tumors and melanomas and as 
for many other tumors, in order to design adequate therapies there is a need to 
understand the nature of these tumors even better. In addition, many of the previous 
animal models for the studies of these tumors have had their limitation, since they have 
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not been able to study the interplay between the tumor and its natural environment and 
the influence the environment has on tumor development and the response to different 
therapeutic modalities. 
 
The ultimate aim of my thesis is to further elucidate the influence of the adjacent tissues 
of a tumor on tumor development and hopefully later also on response to therapy. In 
order to approach this task this thesis has attempted to use a microenvironment 
potentially more relevant to the studies of neuroepithelial tumors and melanoma, all 
neuroectodermal. This microenvironment is derived from a teratoma including various 
human tissues that has developed from human pluripotent stem cell- (hPSC) and more 
specifically from human embryonic stem cells- (hESC). This project is a continuation 
of earlier studies done in our group using the potential of hESC-derived teratomas to be 
a supportive preclinical system. Here I have extended our previous findings on tumors 
cell lines for use on clinical tumor biopsies with an emphasis on studying childhood 
cancers of the nervous system. 
 
1.2 NEUROECTODERMAL TUMORS 
 
Neuroectodermal tumors are derived from –neuroectoderm; the part of ectoderm that is 
to give rise to the embryo’s nervous system. These tumors are the focus of my work in 
this thesis. It concentrates especially on, neuroblastoma, primitive neuroectodermal 
tumor (PNET), and melanoma. Below is a brief introduction of these tumors and a 
more detailed description is presented for neuroblastoma and PNET, the tumors 
dominating in this thesis. 
 
1.2.1 Neuroblastoma (NB) 
 
General introduction 
 
Neuroblastoma is a tumor of sympathetic nervous system (SNS) (Brodeur, 2003). It is 
the most common extra cranial solid tumor in children and the third most common 
childhood cancer in general after leukemia and brain tumor. NB accounts for about 7-
10% of all childhood cancers and nearly 15% of all cancer fatalities in children. The 
median age at diagnosis is approximately 18 months and almost 40% of the cases are 
diagnosed by the age of 1 year (Brodeur, 2003; Maris et al., 2007; Schor, 1999). In 
Sweden 10-20 children are diagnosed with NB every year (Gustafsson G 2007; Träger, 
2009). 
 
NB is assumed to be an embryonic tumor and derived from the derivatives of the neural 
precursor cells of SNS- the neural crest (Brodeur, 2003; Grimmer and Weiss, 2006; 
Nakagawara and Ohira, 2004). The neural crest cells in their turn are derived from 
ectodermal part of the embryo and give rise to a variety of cell types in vertebrates. It is 
a highly migrative transient population of cells present at the dorsal region of the neural 
tube closure, beneath the ectoderm. It gives rise to the multipotent progenitors that 
contribute to the formation of the peripheral nervous system; the enteric nervous 
system; to melanocytes, to Schwann cells, cells of adrenal medulla; and cells of 
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craniofacial skeleton. Most NB tumors arise in the abdomen and especially in the 
adrenal medulla, but they can also occur occasionally at other sites such as neck, chest 
and pelvis (Maris et al., 2007). 
 
 
 
 
Figure 2: Neuroblastoma primary tumors derived from the neural crest arise in the sympathetic 
nervous system including the adrenal medulla, sympathetic ganglia and paraganglia. Neuroblastomas 
mainly metastasize to lymph nodes, bone and bone marrow, and in infants also spread to liver and 
subcutaneous tissue. Reprinted with permission from Springer Science media and Business media, 
(Johnsen et al., 2009) 
 
Different classifications 
 
NB is highly heterogeneous both biologically and clinically. The clinical outcome 
spans from a less aggressive tumor with an ability to spontaneously regress or to 
differentiate into benign ganglioneuromas, to a very aggressive highly metastatic tumor 
with resistance to multimodal therapy. According to the International Neuroblastoma 
Staging System (INSS), NB is classified in to stages 1-4 and 4S (Brodeur et al., 1993). 
Stage 1 tumors are surgically removed localized tumors often less aggressive without 
metastases in bone and bone marrow and easily managed without further therapy 
whereas stage 4, especially in older children, is usually a most aggressive and highly 
metastatic tumor often resistant to multimodal treatment including chemotherapy and 
irradiation. Stage 4S is a special stage, in which infants younger than one year with NB 
have a localized small primary tumor with metastasis in liver, skin or bone marrow and 
it almost always regresses spontaneously or after minimal therapy (Brodeur, 2003; 
Maris, 2010; Maris et al., 2007; Schor, 1999; van Noesel and Versteeg, 2004). 
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NB is also classified into different risk groups according to the risk assessment. A new 
staging system not taking surgical procedure into account has recently been established 
by the International Neuroblastoma Risk Group (INRG) as the INRG Staging System 
(INRGSS) dividing NB into localized and metastatic tumors (L and M or MS, resp) 
(Monclair et al., 2009). A consensus risk classification is now established with this 
staging system and other features as age, histology and genetics that divides NB into 
very low, low, intermediate and high risk groups to be used for clinical management 
and future studies (Cohn et al., 2009).  
 
Based on histology, NB can be graded as a favorable or an unfavorable tumor. The 
International Pathology Classification System (INPC) has established a system to grade 
tumors into good and poor prognosis tumors based on the Shimada histology grading 
system. This system uses criteria based on degree of differentiation, the Schwannian 
stromal content and age at diagnosis (Shimada et al., 1999a; Shimada et al., 1999b). 
 
For staging purposes and prognostic assessment, the detection of widespread disease 
and in particular bone marrow involvement is essential (Brodeur, 1998; Cohn et al., 
2009). Recently within the INRG efforts the consensus criteria for detection of 
neuroblastoma cells in blood and bone marrow were reached (Beiske et al., 2009). 
 
Genetic changes 
 
General: Genetic changes in NB show a close association with tumor stages and 
aggressiveness and can also be used as prognostic factors. Neuroblastoma presents 
complex genetics; the acquisition of a number of genetic aberrations including ploidy 
changes, mutations in certain genes (PHOX2B and ALK), amplification of MYCN, 
loss of 1p, 11q and gain of 17q (Brodeur, 2003; Maris, 2010). Although none of these 
genetic alterations has been found as the single causative factor of NB and also none 
has been found to be generally present in all NB (Bown, 2001; Caren et al., 2010). 
 
Hereditary changes: Hereditary NB accounts for 1-2% NB cases with germline 
mutations in two genes, ALK and PHOX2B (Fisher and Tweddle, 2012). Anaplastic 
Leukemia Kinase (ALK) gene was first identified as a predisposition to familial NB 
and mutations in this gene are now considered to be the most common cause of 
hereditary NB (Janoueix-Lerosey et al., 2008; Mosse et al., 2008) and familial NB 
cases are now subjected for the screening of ALK mutations. Besides hereditary NB, 
mutations in the ALK gene are also present in up to 10% of sporadic NB and in other 
malignancies as well (Fisher and Tweddle, 2012). 
 
Paired Homeobox 2b gene (PHOX2B) is involved in the normal development of 
sympathetic nervous system (SNS) and catecholamine synthesis. Mutations in 
PHOX2B were first identified in Congenital Central Hyperventilation Syndrome 
(CCHS) and are also present in Hirschsprung’s disease, both of them are the diseases 
caused by the failure of neural crest cell migration and are considered to be associated 
with a higher risk of developing NB. In such cases presence of mutations in the 
PHOX2B gene are likely to influence the incidence of NB. Like ALK mutations, 
PHOX2B mutations are also found to be present in some sporadic neuroblastoma cases 
(van Limpt et al., 2004). 
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A brief introduction on other genetic alterations present in NB 
Amplification of MYCN: Amplification of MYCN in NB is associated with a poor 
outcome and it is frequently present in rapidly progressing tumors with advanced stages 
(Brodeur, 2003; Cohn and Tweddle, 2004; Maris, 2010). In 1983, Schwab et al first 
described MYCN amplification at 2p24 (Schwab et al., 1983). Moreover, MYCN 
amplification is present in about 20% of all neuroblastomas (Fisher and Tweddle, 
2012).  
 
Allelic loss of 1p: Allelic loss of 1p is present in up to 35% NB cases and correlates 
with MYCN amplification and advanced disease stages (Attiyeh et al., 2005). Many 
groups have reported 1p deletion as an indicator of worse prognosis.  
 
Gain of 17q: Gain of 17q is the most common genetic aberration in NB and is present 
in up to 70% of the cases (Caren et al., 2010) and is also related to unfavorable 
prognosis. It is very unlikely that a tumor is MYCN-amplified or 1p-deleted without a 
17q gain (Fisher and Tweddle, 2012).  
 
Imbalance in 11q: 35-40% of NB cases have imbalance of 11q (Attiyeh et al., 2005). 
Unlike Loss of Heterozygosity (LOH) of 1p, LOH in 11q is not associated with MYCN 
amplification. Nevertheless, in non-amplified MYCN neuroblastoma, 11q loss is 
predictive of poor prognosis and characterized by older age at diagnosis and 
accumulation of a higher number of genetic aberrations (Caren et al., 2010). 
 
Ploidy: DNA index of the tumor cells has been linked to prognosis of NB. Look et al 
1984 showed that hyperploidy/triploidy, DNA index around 1.5, in children less than 1 
year is linked with early-stage tumors and linked to good prognosis, while diploidy is 
linked to therapy resistant tumors (Look et al., 1984). Tumors with diploid DNA 
content have been shown to harbor unfavorable specific genetic aberrations while 
hyperploid tumors show more favorable pattern of numerical aberrations (Caren et al., 
2010). 
 
1.2.2 PNET 
 
PNET is a group of tumors usually occurring in infants, children and young adults. It is 
assumed to arise from the primitive neuroepithelial cells that are left out from the 
development of central nervous system (CNS) (Leveine Arnold J., 1993). CNS tumors, 
in general account for approximately 20% of all cancer cases in children worldwide and 
are the most leading cause of cancer-related deaths (Heath et al., 2012; Pollack, 2011). 
In Sweden, 28% of the 300 children with a malignant disease annually have a CNS 
tumor (Gustafsson G 2007). PNET can be classified into two major types depending on 
the location of primary tumor, CNS PNET that occurs in the brain and spinal cord and 
peripheral PNET that is present outside the brain and spinal cord. The most common 
type of CNS PNET is medulloblastoma that alone accounts for 20% of all childhood 
brain tumors (Klesse and Bowers, 2010; Samkari et al., 2012). According to WHO 
classification, CNS PNET also includes malignancies like, supratentorial PNET 
(sPNET), cerebral neuroblastoma, CNS ganglioneuroblastoma, medulloepothelioma 
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and ependymyblastoma (Louis et al., 2007; Samkari et al., 2012). CNS PNET, in 
general present a histopathology composed of poorly differentiated neuroepithelial cells 
expressing neuronal markers such as synaptophysin (Samkari et al., 2012). 
 
1.2.2.1 sPNET 
 
sPNET are rapidly growing very aggressive tumors that occur in the cerebrum, which is 
present at the top of the brain and head and makes up the largest part of the brain. The 
cerebrum controls some of very important functions such as thinking, learning, 
problem-solving, emotions, speech, reading, writing and voluntary movements (Snell, 
2009). sPENT accounts for about 2.5%-3% of all childhood tumors (Jakacki, 1999). 
Five-year survival rates range from 30%-47% despite maximal therapy (Albright et al., 
1995; Cohen et al., 1995; Dirks et al., 1996; Paulino and Melian, 1999; Reddy et al., 
2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Parts of brain describing the location of supratentorial. Curtsey for drawing, Isabell Hultman. 
 
 
sPNET are known to have multiple genetic aberrations in contrast to the other CNS 
PNET such as pineoblastomas and medulloblastomas, which have relatively fewer 
alterations (Miller et al., 2011). The most common alterations in sPNET are gains of 
1q, 2p and 19p and losses of 3p21, 3q26 and 8p23 (Dahlback et al., 2011; Miller et al., 
2011). 
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Figure 4: Schematic representation of brain structure. Curtsey for drawing, Isabell Hultman 
 
1.2.3 Melanoma 
 
Melanoma is malignant tumor of melanocytes- the cells that produce a pigment called 
melanin which gives the skin and hair color. Melanocytes are derived from derivatives 
of the neural crest of the human embryo. Melanoma can occur anywhere on the skin 
and is one of the very metastatic tumors. It is the most lethal skin cancers (Jemal et al., 
2010). Although malignant melanoma accounts for 4% of all skin cancers, it still causes 
the highest number of skin-cancer related deaths worldwide, accounting for about 90% 
of skin cancer mortality (Garbe et al., 2012; Maio, 2012). Melanoma is more common 
in Caucasians than in other populations and the increasing rate of incidence in the 
western world is a major health problem (Claeson et al., 2012; Godar, 2011). A recent 
study carried out by Claeson M and colleagues on the incidence of cutaneous malignant 
melanoma in the Swedish population during 1970-2007, describes that the number of 
cases have increased from 557 in 1970 to 2332 in 2007 (Claeson et al., 2012). 
 
Metastasis is the most important predictor of melanoma prognosis (Fernandez-Flores, 
2012). Melanoma can metastasize to any organ (Leong et al., 2011). Even small tumors 
can metastasize, contributing to poor prognosis (Garbe et al., 2012). Resistance to 
therapy is one of the characteristics of malignant melanoma and hence the biggest 
challenge to melanoma treatment (Hocker et al., 2008). 
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Figure 5: A cutaneous malignant melanoma. Reproduced from Wikipedia 
 
Individuals with high numbers of common naevi and those with large congenital naevi, 
multiple and/or atypical naevi (dysplastic naevi) are at greater risk (Bauer and Garbe, 
2003; Garbe et al., 1994a, b; Grobe et al., 1990; Holly et al., 1987). A family history of 
melanoma occurs in about 10% of melanoma patients and confers an approximately 
two-fold increase in melanoma risk (Gandini et al., 2005). The most common 
exogenous factor is UV irradiation (Curtin et al., 2006; Curtin et al., 2005; Tsao et al., 
2004).  
 
Melanoma has shown to have dysregulation of signaling pathways for controlling 
important functions such as cell proliferation, migration and apoptosis. Genetic 
alteration in BRAF and NRAS genes upstream the MAPK/ERK pathway leads to an 
activation of this pathway. Mutations in BRAF occur in approximately half of 
cutaneous melanoma cases (Davies et al., 2002; Hocker and Tsao, 2007). In most of the 
cases a point mutation leads to an amino acid substitution, which results in the 
constitutive activation of the MAPK/ERK pathway (Davies et al., 2002; Palmieri et al., 
2007). One the other hand mutations in NRAS gene, which is upstream of BRAF, are 
present in about 15% of all melanoma cases (Edlundh-Rose et al., 2006; Hocker and 
Tsao, 2007; Omholt et al., 2003; Tsao et al., 2004). These alterations are mainly caused 
by amino acid substitution in codon 61 (Albino et al., 1989; Ball et al., 1994; Platz et 
al., 1994). The PI3K-pathway is also observed to be dysregulated in some malignant 
melanoma cases, and this is mainly caused by an alteration in the tumor suppressor 
gene PTEN (Bastian, 2003; Wu et al., 2003). PTEN is shown mutated in 60% all 
melanoma cases (Goel et al., 2006). Dysregulation of MAPK/ERK and PI3K pathways 
can also be caused due to alterations in one or more upstream receptor tyrosine-kinases 
(RTKs). Mutations in e.g. receptor tyrosine-kinase KIT are present in about 17% of 
melanomas with chronic sun damage (CSD) (Curtin et al., 2006). 
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Melanomas are highly plastic tumors and have a great ability to differentiate into 
multiple cell phenotypes depending on the cues received from the surrounding 
microenvironment and the need of tumor cell progression. An important example of 
this plastic potential is the ability of melanoma to participate in vasculogenic mimicry 
and neovascularization. Melanoma cells are shown capable of differentiating into 
epithelial cells to support tumor growth and progression. Together with high degree of 
therapy-resistance, these characteristics emphasize on the need of preclinical models 
studying factors/cells that support the progression of melanoma and the sustaining of 
these characteristics.  
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1.3 EXISTING PRE-CLINICAL TUMOR MODELS 
 
The efficacy of anti-tumor therapy in the patients largely depends on the preclinical 
model used for testing of the drugs. Hence it is of utmost importance that the model 
systems used should mimic the natural growth environment of the tumors in patients as 
much as possible. For obvious reasons human tumors cannot be experimentally grown 
in humans and in vitro experiments and animal models are the available options left. 
 
1.3.1 In vitro models – advantages and disadvantages 
 
In vitro studies on tumors have since long been contributing to understanding different 
cellular and growth mechanisms of cancers as well as for the therapeutic purposes. In 
vitro tumor models are advantageous to study cancer, because researchers have a great 
degree of control, ease and planning on these experiments. These in vitro platforms are 
cost effective and ethically advantageous over in vivo models. Among the scientific 
advantages, one is that they offer excellent model for studying biological mechanisms 
of actions due to easier measure of effect in simple, well-controlled experiments and 
hence in vitro models have lead to the discovery of many drugs (Sceats). In vitro 
models can reproduce the properties of tumors to varying extent, including the 3-D 
growth and matrix interaction (Levenberg et al., 2003; Seftor et al., 2006). However, 
these models lack the interaction of tumors with the surrounding stroma, and the spatial 
and temporal coordination of a cellular microenvironment is difficult to attain in vitro, 
which may lead to the drugs being effective in vitro but less- or ineffective in the 
patients (Johnson et al., 2001; Kerbel, 2003; Takimoto, 2001). In vivo animal models 
offer solution to most of the limitations of in vitro systems.  
 
1.3.2 In vivo animal models 
 
The first in vivo models for tumors that were developed in the mid-1960s were mouse 
leukemia models (Teicher, 2006). There are many inbred, outbred and transgenic 
species used in laboratories today. Among all the animal models, the species Mus 
musculus is the most extensively studied for transplantation of both mouse and human 
tumors. There are several reasons to choose mice as models of cancer research: 
primarily because they are mammals, small in size, easy to handle and maintain. They 
reproduce quickly and one of the most important reasons is that the whole genome is 
sequenced and resembles the human genome to a large extent. In addition, its life span 
of approximately three years offers scientists to design experiments of varying time 
length.  
 
1.3.3 In vivo mouse models- advantages and disadvantages 
 
Experimental mice models have been used as the primary species for the testing of 
anticancer therapies for over half a century (Kerbel, 2003). Xenografting of tumors in 
athymic (nude) or severe combined immune deficient mice (SCID) is commonly used. 
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Xenografts in mice are mostly developed by engrafting the tumor cell lines or primary 
tumor biopsies either in the original site of tumor growth (orthotopically) or in a 
location easy to access and monitor e.g. subcutaneously in immunodeficient mouse 
models. The development of xenograft models for human cancers was a big step closer 
to achieving more clinically relevant models. The human tumor cell lines can easily be 
injected. In addition, many of these models can be reproduced, a wide variety of tumor 
cell lines can be studied, the host animals are readily available, and a large number of 
animals can be used hence giving a statistically valid data (Teicher, 2006). 
Nevertheless, despite all the above-discussed advantages, xenograft models still offer a 
great limitation. A major limitation is that the surrounding environment for tumor 
growth is non-human. Today it is widely accepted that the influence of surrounding 
human stroma on the growth and progression of tumors is very crucial specially in 
testing the anti-cancer therapies. In a patient the cancer is in a context of a complex 
microenvironment consisting of different cell types including a heterogeneous mass of 
tumor cells, cancer-associated fibroblasts, endothelial cells contributing to 
neoangiogenesis and also the host immune system may or may not contribute in the 
tumor progression. Hence, there is a cross talk between the cells in the cancer and the 
non-tumor surrounding. This is very important to keep in mind when studying tumor 
xenografts in mice, and this may have resulted in the inefficacy of many anti-cancerous 
drugs in clinics. This alteration in the normal tumor architecture of human tumors in 
mouse xenografts i.e. a disturbed interaction of cancer with its non-tumor environment, 
could possibly lead to an increased autonomous regulation of tumor growth. 
Subsequently this could result in a selective pressure from the surrounding leading to a 
growth of a less heterogeneous tumor mass (De Both et al., 1997; Staroselsky et al., 
1992). As a consequence, the therapies developed against these cancers may only be 
effective against the certain cell types, which are allowed to grow under this selection 
pressure and may not give the same efficacy against the primary tumors in patients with 
more heterogeneous tumor masses.  
 
One feature of mice xenograft models of human cancers, especially tumor cell lines, is 
that the tumors grow rapidly, compared to the slower growth rate in the patient. Hence 
the progression of tumors in xenograft does not give the real picture of tumor growth 
progression as it is in patients.  
 
Other more advanced mouse models include genetically modified/Genetically 
engineered mice (GEM) models harboring and expressing mutated genes. The most 
important advantage of GEM mice is that the tumors arise ‘de novo’ in the animals and 
can then be frequently followed over a long period of time. GEMs are good for the 
studies specially where an intact immune system is required (Kerbel, 2003). However, 
the still remaining big shortcoming of these models is that the tumors are still murine 
and not human in nature, and hence the drugs developed against these tumors may not 
be as effective in the corresponding human situation.  
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1.4 STEM CELLS 
 
Stem cells are different from other cells in that they can both self-renew to their 
undifferentiated status, as well as also having the long-term potential to differentiate to 
more specialized cell types (Thomson and Odorico, 2000). Stem cells are thus present 
throughout out life, from the fertilized oocyte to adult stage (Fuchs and Segre, 2000; 
Terskikh et al., 2006).  
 
Stem cells differ on the degree of ‘stemness’- i.e. the potential to differentiate into 
advanced cell types. The highest degree of differentiation potential is totipotency 
possessed by totipotent stem cells and is retained only by the zygote and up to the 
eight-cell stage of the morula. As the embryo goes on dividing, the stem cells become 
limited for their potential to give rise to a complete human body.  
 
1.4.1 Pluripotent stem cell 
 
Pluripotent stem cells are characterized by their capacity of prolonged in vitro self-
renewal in an undifferentiated state, while maintaining their developmental potential to 
differentiate into the derivatives of all the three embryonic germ layers both in vitro and 
in vivo (Schöler, 2007; Ulloa-Montoya et al., 2005). Embryonic Stem Cells (ESC) are 
categorized as pluripotent stem cells together with Embryonic Germ (EG) Cell and 
Embryonal Carcinoma (EC) cells. Martin Evans and Mathew Kaufman derived the first 
embryonic stem (ES) cells from the inner cell mass (ICM) of mice in 1981 (Evans and 
Kaufman, 1981). In the same year, Gail R. Martin also derived a pluripotent stem cell 
line from early mouse embryos (Martin, 1981). The derivation of ES cells from mice 
lead to the derivation of several other ES cell lines from different species including 
primates ES cells from Rhesus monkeys (Thomson et al., 1995) and marmoset 
(Thomson et al., 1996) and eventually to human embryonic stem cells in 1998 
(Thomson et al., 1998). 
 
1.4.2 Human embryonic stem cells 
 
In 1998 the derivation of the first human embryonic stem cell (hESC) lines was 
reported (Thomson et al., 1998). hESC are derived from the ICM of a blastocyst from a 
pre-implantation human embryo i.e. day 5-6 post fertilization. Cells in the ICM are 
pluripotent at that stage but loose their pluripotency as the development proceeds, i.e. 
their pluripotency is a transient condition in the embryo. However if they are extracted 
and cultured under conditions necessary for the undifferentiated state, they can retain 
their pluripotency.  
 
1.4.2.1 Culture 
 
To maintain the undifferentiated status of hESC, strict culture conditions are essential. 
hESC are known to spontaneously differentiate if not kept under optimal culture 
conditions. Basic Fibroblast Growth Factor (bFGF) helps maintain the pluripotency in 
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culture and hence is an important component of ES cell culture medium. To avoid 
biological variation, chemically defined medium can be used and commercially 
available Serum Replacement (SR) can be used instead of Serum. Human ES cells need 
an extracellular matrix support for in vitro culture. The first human ES cell line was 
derived on murine fibroblasts as feeder cells (Thomson et al., 1998). However, efforts 
have been made to avoid animal components as much as possible, and later, several 
other groups including ours, used human fibroblasts as feeder cells. To avoid the use of 
feeders at all, feeder-free support systems today are in use, such as Martigel 
(Klimanskaya et al., 2005; Xu et al., 2001). Feeder based culture is however a robust 
and cost effective alternative and used throughout this study. 
 
For the quality controls in this thesis work, the hESC were tested for a normal 
karyotype, expression of nuclear pluripotency markers Oct-4 and Nanog, and cell 
surface markers Stage-Specific Embryonic Antigen, SSEA-4, Trafalgar; TRA-1-60, 
TRA-1-81, as well as an absence of markers of differentiation (SSEA-1). 
 
1.4.2.2 Self-renewal and Pluripotency 
 
Self-renewal and pluripotency are the two characteristics that give hESCs a great 
potential for expansion and differentiation. Self-renewal means continuous cell division 
while maintaining their undifferentiated state, theoretically giving them a limitless 
proliferative potential. Pluripotency provides a wide developmental potential to 
differentiate in to the derivatives from all the three embryonic germ layers, which 
ultimately give rise to all cells of the human body. Self-renewal and pluripotency are 
strictly regulated at transcriptional- and cell cycle level. Apart from normal karyotype, 
human pluripotent stem cell lines express pluripotency cell surface markers Stage-
Specific Embryonic Antigen, (SSEA)-3, SSEA-4, Tumor Recognition Antigen (TRA)-
1-60, TRA-1-81 and alkaline phosphatase, and absence of markers of differentiation 
(SSEA-1) of any lineage. (Thomson et al., 1998). On a molecular level, certain 
characteristics are known to play a role in maintaining pluripotency in hESCs, such as 
high telomerase activity (Thomson et al., 1998), expression of Oct-4, nanog and sox-2 
(Boyer et al., 2005).  
 
Pluripotency of embryonic stem cells can be verified in three ways; by retransferring 
them into early embryos where they eventually give rise to all somatic cells of the 
chimeric embryo, including the germ cells. For obvious ethical reasons, such an 
experiment cannot be performed in humans but has been done in mice (Brinster, 1974; 
Nagy et al., 1990; Nagy et al., 1993). The other two approaches are to demonstrate that 
ESC can give rise to the derivatives of all the three germ layers in vitro and in vivo 
(Gepstein, 2002). 
 
1.4.2.3 In vitro differentiation 
 
As described earlier that removal of culture conditions maintaining the undifferentiated 
state of hESC may lead to spontaneous differentiation of hESC. This can easily be seen 
in non-adherent multicellular aggregates of hESC called Embryoid Bodies (EB).  
However, to direct in vitro differentiation of hESC into a certain cell type, and to 
demonstrate the pluripotency of hESC in a more controlled manner, various protocols 
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are in use today hESC into desirable specialized cell types neural lineages (Itskovitz-
Eldor et al., 2000; Reubinoff et al., 2001; Schuldiner et al., 2000), hepatic lineage 
(Touboul et al., 2010), cardiac muscle differentiation (Quattrocelli et al., 2012) etc. 
 
1.4.2.4 In vivo differentiation 
 
For human ESCs, in vivo pluripotency is evaluated commonly by induction of benign 
teratomas upon xenografting in Immune deficient mice- containing tissues representing 
derivatives of ectoderm, endoderm and mesoderm (Brivanlou et al., 2003; Thomson et 
al., 1998).  
 
1.5 TERATOMA 
 
As described earlier, teratoma formation is one of the essential criterions for any cell 
type to be classified as pluripotent stem cell. Benign tumors consisting of several 
different types of tissues have been described since 17th century (Birch S, 1683). 
However the term ‘teratoma’ was first coined in 1863 by Rudolf Virchow (Virchow, 
1863).  
 
Teratocarcinomas derived from embryonal carcinoma cells are malignant (Pierce et al., 
1960) and thus distinct from the benign teratomas derived from karyotypically normal 
pluripotent stem cells (hESCs or iPSCs) (reviewed by (Blum and Benvenisty, 2008). 
Moreover, teratocarcinoma has an abnormal aneuploid karyotype (Oosterhuis and 
Looijenga, 2005; Ulbright, 2005). 
 
Experimental teratomas are generically equivalent to tumors, but we and others have 
shown that teratomas derived from pluripotent stem cells with normal karyotypes can 
also be described as a failed embryonic process without a developmental axis, 
including increasingly chaotic embryonic tissues with emerging organoid 
development(Blum and Benvenisty, 2008; Gertow et al., 2004; Lensch and Ince, 2007). 
This is further emphasized in this thesis (Paper I). 
 
Formation of teratoma has been achieved successfully in various sites in the host 
animal e.g. subcutaneously, intramuscularly, intratesticularly or under the kidney 
capsule (Cooke et al., 2006; Gertow et al., 2004; Heins et al., 2004; Plaia et al., 2006). 
We have chosen, for our studies, intratesticular injections because of several reasons. 
Of which some are that it is not vital, it is easily located and accessible, 
immunoprivileged, well encapsulated, keeping the graft in position, and teratoma 
growth can partly be monitored, by examining it externally. It is likely that the hypoxic 
and hormonal local environment of testis may influence the growth of implanted hPSC 
especially at the early stages of teratoma growth when the mouse tissue is dominating 
the microenvironment. However it should be noted, that at the selected time point i.e. 
day 45 of teratoma growth for the injection of tumors, the testis tissue is almost 
completely taken over by the developing PSCT-tissues. 
 
Pluripotent stem cell derived teratomas contain a variety of tissues from ectoderm, 
endoderm and mesoderm. In 2004, Gertow et al from our group presented a thorough 
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analysis of the tissues derived from HS181 cell line teratomas (Gertow et al., 2004). 
The tissues from ectoderm were dominating and moreover neuroepithelium was the 
most dominant ectodermal derivative. Epithelium of other nature was also detected. 
Among the mesodermal derivatives, bones and cartilages were detected. Furthermore 
intestinal and bronchi epithelium of endodermal origin were also detected. These 
teratomas also presented the embryonic mesenchyme of loose and condensed nature.  
  
1.5.1 Vascularization in teratoma 
 
Several studies have shown that hESC are capable of differentiating into endothelial 
cells in vitro as well as in vivo (Gerecht-Nir et al., 2004; Gerecht-Nir et al., 2003; 
Gertow et al., 2004; Levenberg et al., 2002). Immature human vasculature can be seen 
but the major contribution towards vascularization is mainly of the host origin. Vessels 
of human origin can be indicated by positive expression for human CD31 and CD34, 
and were usually seen at later time points. Gertow et al from our group have reported 
the appearance of anastomosis of human / mouse vessels, based on chimeric staining 
for human CD31 (Gertow et al., 2004). 
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2 AIMS 
 
1. To characterize the embryonic microenvironment in human pluripotent stem 
cell-derived teratoma (PSCT).  
Paper I 
 
2. To investigate the feasibility of using PSCT for pre-clinical analysis of human 
tumors, using tumor cell lines. 
Papers II and III 
 
3. To investigate in situ engraftment, growth, and progression of patient tumor 
material in PSCT. 
Paper IV 
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3 MATERIALS AND METHODS 
 
Materials and methods are described in the individual papers in more details. Here I 
have explained in a more sequential manner, step-by-step, collectively for all the papers 
to give a general idea of the experimental design. Below is a flow chart summarizing 
the materials and methods of the experimental design for all four articles, illustrated in 
Figure 6. 
 
 
Figure 6: Flow chart of experimental design. 
 
All the studies in this thesis were started with the culture and injections (teratoma 
formation) of Pluripotent stem cells (PSCs). 
 
3.1 PLURIPOTENT STEM CELLS (PSCS) [PAPER I-IV] 
 
3.1.1 Human Embryonic Stem Cells (hESC) 
 
The human embryonic stem cell lines HS181 (Hovatta et al., 2003) and H9 (Thomson 
et al., 1998) are the two cell lines that are used to carry out experiments in paper I-IV 
and paper II, III respectively. Both cell lines were derived from the inner cell mass of 
human blastocyst and have normal female genotype i.e. 46[XX].  
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3.1.2 Culture conditions 
 
HS181 and H9 were cultured on human foreskin fibroblast cells (hFS) (CRL-2429; 
ATCC) as feeder cells. hFS were cultured in Iscove’s Modified Dulbecco’s Medium 
(IMDM) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (all from 
Invitrogen). hFS were mitotically inactivated either by irradiation with 35 Gy before 
seeding [paper I] or by treatment with mitomycin C (10 µg/ml, 3hours) [paper II-IV]. 
The fibroblasts were then seeded at 2x104 cells/cm2 on 6-well plates (BD Falcon). 
 
hES were cultured in Knock-Out Dulbecco’s Modified Eagle Medium (KO-DMEM) 
containing 20% Knock-Out Serum Replacement (KO-SR), 2 mM L-glutamine, 1% 
nonessential amino acids, 0.1 mM β-mercaptoethanol, 4ng/ml basic fibroblast growth 
factor (bFGF) (all from Invitrogen). Cells were cultured at 37°C, and 6.8% CO2 and 
high humidity (95%). Culture medium was changed daily. The cells were passaged 
using Dispase (10mg/ml) (Invitrogen) for 5-7 min at 37°C with mild mechanical 
separation. 
 
In paper III, two other pluripotent stem cell lines were used to generate teratomas. 
Following are the details about these lines. 
 
3.1.3 Human induced Pluripotent Stem Cells (hiPSC) 
 
hiPSCs were kindly provided by Dr Ludovic Vallier , University of Cambridge, UK 
(Vallier et al., 2009). These cells were derived from adult dermal fibroblast and were 
grown in Advanced DMEM⁄F-12 (Invitrogen) supplemented with 20% (v/v) Knockout 
Serum Replacement (Invitrogen), 2mM L-glutamine (Invitrogen), 0.1mM B-
mercaptoethanol (Sigma) and 4ng/ml basic Fibroblast Growth Factor (bFGF, R&D). 
 
3.1.4 Mouse Embryonic Stem Cells (mESC) 
 
mESC RW-4 were kindly provided by Dr Stephan Teglund, Karolinska Institute and 
were originally derived from inner cell mass of mouse blastocyst. mESC were cultured 
on murine embryonic fibroblasts (MEFs) as feeders cells in Dulbecco’s Modified Eagle 
Medium (DMEM) (Gibco) containing 15% FBS (Göteborgs Termometerfabrik). 
 
3.1.5 Quality control 
 
Mycoplasma: All experiments were performed on Mycoplasma free cell cultures. 
Mycoplasma infections were screened using EZ-PCR Mycoplasma Test Kit (Biological 
Industries). Cell were cultured for 3 days without changing medium and supernatant 
was tested for the presence of Mycoplasma using the PCR reaction mix, according to 
the manufacturer’s recommendations. The experiments were performed together with a 
positive control provided with the kit. 
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3.1.6 Pluripotency 
 
RT-PCR: In vitro pluripotency of hESC was routinely characterized by RT-PCR for 
markers of pluripotency. Two different RNA extraction methods were used for this 
purpose, RNA was extracted using Micro-to-Midi kit (Invitrogen) from in vitro 
cultured cells or EBs [Paper I] and TRIzol extraction was used in paper II-IV. 
Preparation of cDNA and PCR methods was same as described in sections 3.5.4 and 
3.5.5. 
See Table 2 for details on Primers (Cybergene) and conditions used for characterization 
of hESC. 
 
Table 1:  RT-PCR; primer sequences and conditions used for characterization of hESC. 
 
Gene Primer sequence Size 
(bp) 
Annealing 
Temp (°C) 
mM 
MgCl2  
β - actin F:5´-GACATTAAGGAGAAGCTGTGCTATGTT-3´ 
R:5´-GCCTAGAAGCATTTGCGGTGGACGA-3 
497 58 3.0 
GAPDH F:5´-GCTCAGACACCATGGGGAAGGT-3´ 
R:5´-GTGGTGCAGGAGGCATTGCTGA-3 
470 55 3.0 
Nanog F:5´-CGGCTTCCTCCTCTTCCTCTATAC-3´ 
R:5´-ATCGATTTCACTCATCTTCACACGTC-3 
960 57 1.5 
Oct4 F:5´-AGGATCACCCTGGGATATACACA-3´ 
R:5´-AAGCTAAGCTGCAGAGCCTCA-3´ 
113 55 3.0 
hTERT F:5´-CGGAAGAGTGTCTGGAGCAA-3´ 
R:5´-GGATGAAGCGGAGTCTGGA-3´ 
147 51 1.0 
Klf4 F:5´-CTGCGGCAAAACCTACACAA-3´ 
R:5´-GGTCGCATTTTTGGCACTG-3´ 
182 51 3.0 
  
ICC: hESC were characterized for markers of pluripotency by performing 
Immunocytochemistry (ICC) in papers II-IV. For this, cells were fixed in 4% PFA, 
permeabilized using 0.25% Triton X. Unspecific binding was blocked using 3% Bovine 
Serum Albumin (BSA). Primary antibodies were applied for either 1 hour at room 
temperature or overnight at 4°C, followed by application of secondary antibody for 30 
min. Cells were counterstained with DAPI and Zeiss Table 3 shows the details of these 
experiments. 
 
Table 2: Antibodies used for hESC characterization. 
 
Antibody Dilution Source 
Oct4 1:50 Chemicon, MAB4401 
Nanog 1:50 R&D, AF1997 
TRA1-81 1:50 Chemicon, ab90233 
TRA1-60 1:50 Chemicon, ab90232 
SSEA-4 1:50 Chemicon, ab90230 
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3.2 PSCT-DERIVED TERATOMA IN SCID-BEIGE MICE: [PAPER I-IV] 
 
3.2.1 Animals 
 
Animal experiments were carried out on 6-8 weeks old male Severe Combined 
Immunodeficiency (SCID)-beige (C.B.-17/GbmsTac-scid-bgDF N7) mice, obtained 
from M&B, Denmark. SCID-beige mice carry two mutations; SCID mutation that 
results in lack of B and T lymphocytes and Beige mutation that causes impairment of 
NK-cell function and macrophage defects (Croy and Chapeau, 1990; MacDougall et 
al., 1990).  
 
Animals were kept at the MTC animal facility using the following conditions: 
temperature at 20°C to 24°C, 50% relative humidity, 14 /10 hour light-dark cycle.  The 
animals were kept with food and water ad libitum.  
 
How it was done 
 
PSC-derived teratoma formation was performed by the injection of 1x104 -1x105 PSCs 
in 20µl culture medium under the testis capsules of 6-8 weeks old SCID-Beige mice 
under anaesthesia (3.0 % isofluran). 
 
PSC were mechanically cut and collected in a 1-ml syringe with 27G¾´´ Nr. 20 0.4-
19mm grey needle (both from BD Falcon) immediately prior to injection. The cells 
were allowed to engraft for 6-8 weeks resulting in a benign teratoma containing the 
tissues from all three germ layers.  
 
In paper I, the experiments were terminated at this stage and the teratomas were 
extracted at indicated times points for analysis (Sections 3.4 & 3.5). In Paper II-IV, 
either tumor cells or a piece of tumor from surgery was inoculated into 45-60 days old 
teratomas. Details are as follows. 
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Figure 7: Intratestis injection of pluripotent stem cells to induce PSCT. 
 
3.3 TUMOR INOCULATIONS: [PAPER II-IV] 
 
3.3.1 Tumor cell lines 
 
BL-Melanoma cell line: [Paper II] was previously derived from a lymph node 
metastasis of a malignant melanoma from a male patient treated at Karolinska 
University Hospital (Salazar-Onfray et al., 2002). 
 
Neuroblastoma (NB) cell lines: [Paper III] Three Neuroblastoma cell lines IMR-32, 
Kelly and SK-N-BE (2) were used. NB cell lines were obtained from ATCC. 
 
IMR-32: was derived from the abdominal tumor mass of a 13-months old Caucasian 
male neuroblastoma patient. The tumor line has an amplification of MYCN gene, 
together with partial chromosome 1 deletion (Tumilowicz et al., 1970). 
 
Kelly: was derived from a brain metastasis of neuroblastoma. It has MYCN 
amplification, gain of chromosome 17q, and deletion of 11q as the major aberration. 
 
SK-N-BE (2): was derived from the bone marrow metastasis of a disseminated 
neuroblastoma after repeated cycles of chemotherapy and radiotherapy from a two year 
old child in 1972. The tumor has an amplification of MYCN and a deletion in tumor 
suppressor gene p53. 
 
All tumor cell lines were cultured in Iscove’s Modified Dulbecco’s Medium (IMDM) 
with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (all from 
Invitrogen).   
All tumor cell lines were tested for mycoplasma absence by PCR discussed above 
(section 3.1.5). 
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3.3.2 Clinical tumors 
 
In Paper IV, fresh or frozen clinical tumor biopsies from surgery were 
injected/inoculated into the pluripotent stem cell derived-teratoma (PST) or as 
xenografts. Tumor specimens were received from pediatric patients at the Karolinska 
University Hospital for the studies.  
 
Selection criteria for tumors included neuroectodermal origin with male gender: i.e. 
stable Y-chromosome or presence of a tumor genetic marker e.g. amplification of 
MYCN gene to enable the distinction of tumor cells from the PSCT-cells (originated 
from the female; 46XX HS181 cell line). Total nine patients were recruited for the 
study, out of which three female patients without amplified MYCN were not used in 
experiments for technical limitations. Fresh tumor material was collected at surgery and 
transported to the laboratory as fast as possible (15 minutes). In the laboratory the 
material was divided into aliquots using a scalpel. One aliquot was injected into the 
PSCT in vivo model as fast as possible (within one hour). Cryopreservation of aliquots; 
DMSO were saved in liquid nitrogen to be thawed at chosen time points. 
Table 1 below, briefly describes the diagnosis and clinical history of the six patient 
tumor samples used in the study, for more details please see, Table 1 in Paper IV.  
 
Table 3: Details of surgical tumors used in Paper IV.  
 
 Diagnosis Stage Type of biopsy Chr. 
Aberration 
Patient 1 Supratentorial 
Peripheral 
Neuroectodermal 
Tumor (sPNET) 
2nd relapse very 
aggressive 
irradiated and 
chemo 
Surgical biopsy, 
pieces of tumor 
Not done 
Patient 2 PNET-like tumor Undifferentiated 
infratentorial 
tumor with 
sarcomatous 
features of 
supposed 
neuroectodermal 
origin 
Primary tumor 
 
Molecular 
analysis did 
not find any 
evidence of 
translocation 
Patient 3 Pilocytic 
astrocytoma of the 
brainstem 
low malignancy  Primary tumor 
Hydrocephalous 
N/A 
Patient 4 Classic 
Medulloblastoma 
highly 
malignant 
Primary tumor Not done 
Patient 5 Esthesio 
Neuroblastoma 
Non--irradiated Primary tumor EwS-Fli1 
translocation 
Patient 6 Neuroblastoma M (INRG), 4 
(INSS) 
Metastasis in 
skull, first 
relapse 
11q- 
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3.3.3 Tumor inoculation in xenograft and PST  
 
How it was done 
 
Cell lines: Adherent tumor cells were enzymatically detached, counted, and suspended 
in ice-cold PBS (kept on wet ice), and 20µl PBS containing 1-2x106 viable tumor cells 
injected either directly under the testis capsules of anesthetized SCID-Beige mice as 
xenograft or into the PST. Tumors were allowed to engraft for two weeks before the 
material was extracted.  
 
In Paper II, xenografts of BL melanoma cell lines were also made subcutaneously. (See 
Paper II for details). 
 
Clinical tumors: Tumors were either inserted as a small piece (1mm3) or injected as 
cell suspension. In most of the PSCT cases and in some xenografts, the tumor was 
inserted as a small piece by either making a cut by a sharp surgical disposable scalpel 
(BRAUN, Aesculap Division) or making a hole by a 20G 1½´´ Nr. 1 0.9-40mm yellow 
needle tip (BD Falcon) in the testis and/or PSCT. In case of PSCT, due to the fluid 
pressure from inside, it was extremely hard to make the tumor piece stay inside the 
teratoma, that’s why a suture was made on the teratomas on most of the cases using 
Vicryl 199mm ⅜ c sutures (Ethicon). For more details on individual samples Please see 
Table 2 in Paper IV. 
 
Cell suspension was made by plunging with the plunger of a 5-ml syringe (BD Falcon) 
and filtering the cell suspension through 70µm Nylon cell strainer (BD Falcon) The 
suspension was then injected as xenograft or in PST using a 1ml-syringe (BD Falcon) 
and 27G¾´´Nr. 20 0.4-19mm grey needle (BD Falcon). 
 
3.4 EXTRACTION: [PAPER I-IV] 
 
The extraction method was the same in papers I-IV, but differed regarding the time 
point for extraction. In paper I, PSCT were extracted at indicated time points (Day 5, 
10, 20, 30, 45 and 60). In papers II and III, PSCT/tumors containing tumor cell lines 
and tumor xenografts were extracted two weeks after the injection of tumors cells. 
  
In paper IV, the shortest observation period was 18 days and the longest period of 
growth of clinical tumors was 90 days. The upper limit was determined by the humane 
endpoint from the host animal point of view, i.e. before the PSCT/tumor reached a total 
size of 15 mm diameter (allowed according to the ethical permit). 
 
How it was done 
 
After the end point of experiment was reached, the animals were sacrificed by cervical 
dislocation and teratoma [Paper I]/teratoma+tumor and tumor xenografts [Paper II-IV] 
were harvested.  
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In papers I and IV, the material was divided in two halves with a sharp blade for either 
histology or cryopreservation. In Paper II and III, all the tissues were fixed in 4% 
Paraformaldehyde (PFA) since only histological analysis was done and no RNA was 
extracted. 
 
3.4.1 PFA-fixation 
 
One half of harvested material was fixed in 4% PFA overnight at 4°C. The tissues were 
dehydrated through a series of alcohol to xylene, embedded in paraffin and serially 
sectioned into 5µm thick sections for analysis. Non-injected testes were also fixed in 
the same manner to use as negative control for FISH experiments [Paper I]. 
 
3.4.2 Snap freezing 
 
The other half of the extracted material was snap frozen in liquid nitrogen and saved in 
-80C until used. In paper I, frozen material was used to extract RNA. In paper IV, 
frozen material was saved to enable further analysis in future.   
 
3.5 ANALYSIS: [PAPER I-IV] 
 
PFA-fixed tissues were used for the following techniques: 
 
3.5.1 Histology: Hematoxylin & Eosin (H&E) 
 
Standard H & E was performed on 5µm thick sections to detect the engraftment of 
hESC [paper I] and to study the histology of engrafted tumors [paper II-IV]. 
 
Histology, and details of tumor cell differentiation was performed accordingly to 
routines used in daily clinical practice and as described (Joshi et al., 1992; Shimada et 
al., 2001) and in a previous study (Gertow et al., 2007).  
 
This part of the project was performed in collaboration with experienced pathologists, 
Bengt Sandstedt (Karolinska Institutet; department of women’s and children’s health 
and Danderyds Hospital), Jurate Skikuniene (Karolinska Institutet, department of 
Onclology and Pathology Karolinska University Hospital), and Luigi Strizzi, 
(Children's Hospital of Chicago Research Center, Cancer Biology and Epigenomics 
Program, Robert H. Lurie Comprehensive Cancer Center, Northwestern University 
Feinberg School of Medicine, Chicago, Illinois, USA). 
 
3.5.2 Fluorescent In Situ Hybridization (FISH) 
A human specific FISH probe (Spectrum Red labeled total human genomic DNA, 
Vysis Inc) was used to verify the engraftment of hESC in the testis and also for the 
human origin of the formed tissues. [Paper I]. In paper II-IV, engraftment of XY 
tumors with stable Y chromosome was detected by the X and Y-chromosome specific 
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FISH probe (CEP X SpectrumOrange CEP Y SpectrumGreen, Vysis Inc.), and the 
tumors without a stable Y-chromosome and female tumors having MYCN 
amplification were detected by a FISH probe LSI n-myc, 2p24 (Vysis Inc.). 
Xenograft sections from the tumor cell lines were used as positive control, and 
xenografts from tumors lacking a Y-chromosome or NMYC amplification were used as 
negative control.  
 
The recommended protocol by manufacturer was same for all the probes except for 
variable hybridization temperature for different probes. Briefly, the sections were 
deparaffinized using xylene, rehydrated using a series of Ethanol and water. Sections 
were then pretreated by boiling in Citrate buffer (pH 6.0) and pepsin at 37°C for 5 min. 
At 75°C for 5 min, double-stranded DNA and probe was denatured, probe 
hybridization was carried out at recommended temperatures (either 37°C or 42°C) 
overnight. Sections were fixed with Vectasheild containing DAPI.  
 
FISH to verify the presence of Y-chromosome or NMYC amplification, was used also 
on tumor cells in culture. For this purpose, cells were grown on gelatine-coated glass 
chamber slides, fixed by ice-cold methanol for 5 min, and immediately treated for 
denaturation and hybridization with the same procedure as described for tissue sections. 
 
 
Figure 8: Growth of clinical neuroblastoma in PCST. To the left, NB is growing in areas of loose 
mesenchyme (blue arrows). Upper right photo illustrates the positive detection of tumor cells (yellow 
arrows) using a XY chromosome specific FISH probe. Lower right photo shows the tumor growth (blue 
arrows) close to the blood vessels (red arrows). (X=red, Y=green)  
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3.5.3 Immunohistochemistry (IHC) 
 
IHC is extensively used in all papers to study protein expression of tumors, and in 
paper I to analyze the protein profile of different stages of teratoma formation, using a 
broad panel of antibodies. Paraffin-embedded PFA-fixed sections were used for these 
experiments. Sections were pretreated according to the optimization protocol of each 
antibody used. It was either boiling in low pH buffer (for example Citrate buffer), or 
high pH buffer (like Tris-EDTA buffer), or in some cases no pretreatment was needed. 
(See individual papers for details regarding conditions and secondary detection system 
used [Paper I-IV]). 
 
Sections known to express the protein of interest were used as positive control and 
tissues known to be negative for markers and use of unspecific isotype antibodies were 
employed for negative control experiments.  
 
Snap-frozen tissues were used for RNA extraction  
 
3.5.4 RNA extraction  
 
In paper I total RNA from half teratomas was extracted using TRIzol reagent  
(Invitrogen) according to manufacturer’s protocol. Extracted RNA was DNAase-
treated using DNase 1 amplification grade (Invitrogen) to avoid contamination of 
genomic DNA. Complementary DNA (cDNA) was synthesized from 20ng RNA, using 
Superscript III First Strand Synthesis System (Invitrogen) according to the 
recommended protocol.  
 
3.5.5 RT-PCR 
 
RT-PCR was done on the cDNA obtained from total RNA (See above), using Platinum 
Taq DNA polymerase (Invitrogen).  
See Table S3 in Paper I for Primers used in Study I. 
 
3.6 ETHICAL CONSIDERATIONS 
 
This study was performed in strict accordance with permission for experiments using 
human embryonic stem cells, from the Local Ethics Committee at Karolinska Institute 
(114/00), and for animal experimentation from the regional ethical committee 
(Stockholms norra djurförsöksetiska nämnd; Dnr S172-03 and N105/07). Collection of 
fresh clinical material from primary surgery at the Karolinska University Hospital was 
performed with permission number 2008/307-31.   
 
3.7 IMAGE ANALYSIS 
Image analysis was done using a Zeiss Axiovert 200M microscope and Q-Imaging 
software.  
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I 
Experimental teratoma forming the basis of the PSCT model 
 
Aims of the study 
One way of verifying pluripotency of human stem cells is to produce experimental 
teratomas, representing tissues from all three germ layers, upon xenografting into 
immunodeficient mice (Brivanlou et al., 2003; Thomson et al., 1998). Ectopic 
implantation of human pluripotent stem cells in mice results in differentiation defined 
as the formation of experimental teratoma, and karyotypically normal stem cells induce 
benign development.  
 
These teratomas are generically referred to as a tumor, but it has previously been 
reported that benign pluripotent stem cell induced teratomas (=PSCT), can be 
described as a failed embryonic process including increasingly chaotic embryonic 
tissues within emerging organoid development (Blum and Benvenisty, 2008; Gertow et 
al., 2004; Lensch and Ince, 2007). Furthermore, despite lacking a developmental axis, 
such components can show striking similarities to the events in the human embryo. 
 
The teratoma assay has been used to validate in vivo pluripotency of stem cells since 
the 1950th (Stevens and Little, 1954) but still little is known about the most early 
developmental processes in vivo leading to the formation of mature experimental 
teratomas. Here, we reported for the first time a kinetic analysis of events taking place 
during the HS181 development in vivo, starting from the very early time point, day 5 
post injection, with a gradual progression in to mature teratoma until day 60. The study 
also attempted to align the events in the development of hESC-derived teratoma with 
that of normal human embryos; an effort to find similarities to normal human 
development.  
 
The main findings of this study were as follows: 
 
Early events of HS181 development resemble initial multiple epiblast formation 
 
A well-characterized human embryonic stem cell line, HS181, was injected under the 
testis capsule of the immunodeficient SCID-beige mice for kinetic studies on teratoma 
formation. Engraftment of/teratoma formation from HS181 cells was analyzed at 
specified time points, day 5,10, 20, 30, 45 and 60 post injection. The human origin of 
the engrafted cells was determined by human specific FISH probes and the growth was 
then analyzed using a large panel of antibodies and RT-PCR markers. Engraftment and 
active proliferation of hESC progeny was detected already at the first observation time 
point, day 5. Multiple sites of engraftment were characterized by the presence of single 
or pseudostratified columnar epithelium, surrounding small cavities, resembling 
embryonic ectoderm also supported by histological analysis. The neural nature of 
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growing ectoderm was supported by the expression of early neural marker NESTIN in 
all epithelia in this stage.  
 
Expression of markers such as Oct4, Nanog, SSEA-4 and KLF-4 supported the 
formation of epiblast-like structures. The histology and marker analysis of the primitive 
ectoderm at this stage was well aligned with Theiler Stage (TS) 8 in mouse and 
Carnegie Stage (CS) 5 (gestational day 7-12) (Larsen, 2001) in human embryonic 
development. Understanding of the early development of HS181 cells is important with 
respect to finding out what these cells actually represent in vivo, i.e. what natural 
counterparts they have. Cells in ICM do not sustain prolonged self-renewal and hESC 
can be regarded as an in vitro artifact.  Our findings suggest that “growth” from HS181 
cell at this stage resembled epiblast formation in embryonic development.  
 
Advanced structures appeared following development at day 30 
 
By day 30, teratomas developed into diverse tissue types, causing almost complete 
destruction of the mouse testicular parenchyma. Expanding multi-layered epithelium 
still maintained dominance in tissue distribution. However, other structures were also 
observed, e.g. a structure with characteristic features of early limb was seen in one 
exceptional case. This showed a centrally condensing mesenchyme positive for CD56, 
(marker for limb morphogenesis and early pre-cartilaginous development) covered by 
thin two layered P63 and E-cadherin positive epithelium with peripheral layer also 
expressing CK18, an IHC profile similar to that of early epidermal development. 
 
Organized and complex structures appeared at day 60 
 
In mature teratomas (days 45-60), more complex structures representing tissues 
originating from all three germ layers were found, although in a disorganized manner 
and lacking a developmental axis. Neuroectodermal structures were still predominant 
but also tissues of non-neural nature were observed, such as early gut and bronchi-
epithelium, renal structures representing presence of intermediate mesoderm, and 
cartilage of mesodermal or eventually ectodermal neural crest origin. Although a 
restricted in vivo potential for development of HS181 derived tissues was indicated by 
the absence of mesoderm structures compatible with somites and also lack of structures 
suggesting early heart formation throughout the study. Somites are derived from 
mesoderm development and give rise to vertebrae, rib cartilage, musculature and skin 
of the back, the ribs and the limbs, tendons and some blood vessels but also specify the 
migration paths of other parts of embryo such as migration of neural crest cells 
(Bronner-Fraser and Stern, 1991; Keynes and Stern, 1984; Teillet et al., 1987). Absence 
of somites may have played a role in the chaotic distribution of tissues. Neural 
dominance was apparent at all stages of teratoma formation, which could also be a 
possible explanation of restricted development of hESC progeny. One possible 
explanation of the strong bias for neural development could be a predisposition for the 
neuroectodermal lineage already in the cultured HS181 cells i.e. before injection. 
 
A rare finding at day 60 was the detection of advanced structures compatible with renal 
development, found in association with the condensed mesenchyme of nephrogenic 
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character, and positive for WT1 staining, and with partially vascularized primitive 
glomeruli and tubuli.  
 
HS181 teratomas were even at day 60 well encapsulated and expanding rather than 
infiltrating the testicular capsule, with no evidence of malignancy.  
 
A unique approach used in this study was to compare morphologies of different 
structures in the HS 181 derived teratoma development with that of original human 
development in the embryos at diagnosed gestational ages. This comparison revealed 
minor differences in the timeline and histology of developing structures. 
 
Three notable observations support this notion. One was the above-mentioned 
development of a limb bud. In human development upper extremities appear from 
CS12 corresponding to gestation day (GD) 28 followed by the emergence of lower 
extremities at CS14 corresponding to GS 33-35. The observation in PSCT at day 30 
(i.e. ICM culture/differentiation for 6 days – in vitro expansion with impeded 
differentiation – and in vivo differentiation for 30 days in PSCT) indicated an 
approximate agreement with the developmental timeline of GS 28-35 for human 
embryos to develop upper / lower limb buds. 
 
Two other observations at day 53 of a single case of trachea-like embryonic structure 
with suggestive respiratory epithelium as well as a most advanced structure of a single 
neural tube like structure were both similarly time matched with only a one week 
discrepancy to reference material from a human embryo approximately CS21-22 
corresponding to GD 53-56. 
 
Several studies have shown that hESC are capable of differentiating into endothelial 
cells in vitro, but showing only immature vessel formation in vivo (Gerecht-Nir et al., 
2004; Gerecht-Nir et al., 2003; Gertow et al., 2004; Levenberg et al., 2002). In HS181 
teratoma development, vascularization was mainly of the host origin although 
immature vessels of human origin, positive for human CD31 and CD34, were also seen 
at later time points. Appearance of partly chimeric vessel structures was observed, 
indicating anastomosis of mouse and human vessels. 
 
4.2 PAPERS II-IV 
The need for better pre-clinical models and the use of the PSCT model 
 
In pre-clinical drug development, accurate prediction of efficacy in patients is essential. 
For the field of oncology however, the attrition rate in clinical trials is unacceptably 
high, reaching levels of 95%, in spite of preceding promising data in pre-clinical 
studies (Hutchinson and Kirk, 2011). Although the background for this is 
multifactorial, novel in vivo models better capturing the relevant neoplastic niche, is 
clearly of great advantage. Pre-clinical studies on human tumors would, for increased 
clinical relevance, benefit from better capturing the neoplastic niche, i.e. permitting 
growth and progression to occur in the relevant in situ environment. 
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Importance of the microenvironment  
 
As described earlier, currently used animal models, mainly xenografts and genetically 
modified animals, entail either the study of non-human cancer, or human cancer in a 
non-human environment, i.e. conditions that do not fully reflect the circumstances in 
the patient. Experimental environments that better mimic the natural milieu would be 
advantageous. 
 
The ability of tumors to invade host tissues and metastasize is dependent on tumor-host 
interactions mediated by several molecular routes that normally enable important 
physiological functions, such as morphogenesis, neurogenesis, and angiogenesis for 
review see e.g. Geho et al. (Geho et al., 2005). Due to the cellular origin of the tumors 
studied in this project, markers related to neural crest migration are of particular interest 
here. Expression patterns of such molecules may be explored both as prognostic 
markers as well as possible therapeutic targets. Hence, current consensus supports the 
importance of a strong interplay with the surrounding tissue promoting tumor growth 
and spread. Many of the anti-angiogenesis drugs proposed in cancer therapy have been 
shown to play a central role in cell migration, firstly for the cells in the vessels, but 
possibly also for the tumor cells per se.  
 
4.2 PAPER II 
Aims of the study 
As discussed above, animal models may not provide an appropriate system for studying 
human cancers and their treatment because of species differences. This paper 
concentrates on detecting advantages of a human cellular microenvironment, and thus 
species-specific interactions, in molecular studies of human tumor progression and 
invasiveness.  
 
Tzukerman et al has previously described how experimental teratoma (see Paper I) can 
provide a general growth support for various human tumor cell lines (Tzukerman et al., 
2003; Tzukerman et al., 2006). Here we take the teratoma model further from the 
original findings described by Tzukerman (Tzukerman et al., 2003; Tzukerman et al., 
2006). We used a malignant melanoma cell line BL, inoculated into PSCT (in this 
publication referred to as the “hEST-model”) from two human embryonic stem cell 
lines, H9 and HS181 as well as mouse xenografts. Melanoma tumors were allowed to 
grow for two weeks and the growth was compared. BL melanoma cells were identified 
using XY chromosome specific FISH probe and the histology was compared by H&E 
staining. A wide panel of markers was used to compare the histopathological profile of 
the tumors growing in different model systems. A comparison was also done with the 
original patient tumor using the findings on the original sections from the patient 
archives.  
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The main findings were as follows: 
 
Analogous histology of BL tumor in xenografts and PSCT model 
 
Tumor histology showing high cellular density and low stroma contribution, from all 
the models was analogous, consisting of pleomorphic cells growing in a delimited 
densely packed manner. Melanoma cells showed highly malignant appearance with 
large nuclei, distinct nucleoli and a less prominent cytoplasm. Comparison from 
archival H&E-stained sections from the original tumor revealed that this cellular 
morphology was also similar to that of original BL patient.  
 
Differences in cellular differentiation markers 
 
Although showing similar histology, some differences in expression of melanoma 
specific markers were seen on tumors from different models. MelanA along with 
HMB45 and tyrosinase, are used as diagnostic markers for melanoma. BL melanoma 
growing as a xenograft showed high expression of HMB45, MelanA and Tyrosinase, 
while tumor cells in the PSCT were negative for these markers. Historical information 
from patient journal shows that the original tumor from the patient metastasis was 
diagnosed with only partly HMB45 staining and no MelanA expression. Hence 
xenograft model directed tumor cells to differentiate, while in PSCT the cells 
maintained a more undifferentiated state similar to the original patient metastasis and in 
vitro cultured cells. 
 
PSCT-specific features of BL melanoma 
 
Tropism 
 
The BL tumor showed some special characteristics, while growing in the PSCT, which 
were not present in tumors growing as xenografts. A clear tropism was seen in the 
tumor integration process. For practical reasons, BL cells could not be directed to 
specific areas inside the teratoma and hence were injected in random positions in 
teratomas. Interestingly, BL showed an exclusive tropism for engraftment by almost 
always growing in areas compatible to condensed mesenchyme, analogous to neural 
crest development. Tumor cells were never found engrafted in areas other than 
condensed mesenchyme e.g., areas compatible with the primitive neuroectodermal 
development, secretory epithelial structures, cartilage etc. or in other organoid 
structures.  
 
Human neovascularization in PSCT upon BL melanoma injections 
 
Engraftment of BL tumor cells induced extensive neovascularization in the PSCT 
environment. BL cells were found surrounded by human vessels in the adjacent human 
stroma, indicated by positive staining for human CD31. As described previously by 
others and us the mature human vasculature in the teratoma is generally weak and the 
blood supply in teratoma is mainly from host (Gerecht-Nir et al., 2004; Gertow et al., 
2004). Possibly, the integration of melanoma cells in the teratoma was initially 
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prioritized close to the mouse vessels, and the neo-angiogenesis in the surrounding 
stroma was a later event.  Our findings are in line with the findings of Tzukerman et al 
who reported strong vascularization adjacent and within the tumor mass of A431 
epidermoid carcinoma cell line growing in a similar teratoma model (Tzukerman et al., 
2006). Contrary to Tzukerman et al, we found that the vessels within the tumor mass 
were of mouse origin.  
 
Melanoma cells are known to induce vasculogenic mimicry, i.e. to support their own 
growth and progression by directing tumor cells to endothelial differentiation, which is 
usually indicated by the up-regulation of VE-cadherin (Carmeliet, 2003). This way 
tumor cells can participate in angiogenic process. Here, however the endothelial lining 
of human blood vessels was detected to be derived from hESC indicated by XX 
karyotype on FISH.  
 
Additional more aggressive and metastatic BL phenotype in PSCT 
 
The BL cells did not exhibit invasive behavior in xenografts, but did so in the PSCT 
model, as suggested by morphology supported also by the expression of S100A4 and 
Nodal. In PSCT exclusively, an additional, apparently more aggressive phenotype of 
BL cells was seen located at the borders of or infiltrating into the surrounding human 
loose mesenchymal fibrous stroma, forming an invasive front, which was positively 
identified by FISH analysis. These migratory cells had a desmoplastic, spindle-like 
appearance, expressing markers indicative of dedifferentiation and migration. 
Immunohistochemical findings of markers related to migrations and invasion was also 
in line with the phenotype of these cells, such as the S100A4, which is a marker of 
malignancy, was found exclusively in the invasive fronts in tumors growing in human 
teratoma model. The expression of S100A4, in xenograft was dispersed in single cells 
within the tumor mass. Nodal, another marker linked to dedifferentiation is known to 
be overexpressed in aggressive metastatic tumors including melanoma (Postovit et al., 
2008; Topczewska et al., 2006), was only found dispersed in some tumor cells growing 
as xenograft but was focally exclusively expressed in the tumors cells lining the 
invasive front while growing in PSCT and not expressed in other parts of the tumors. 
Nodal is an embryonic morphogen belonging to the transforming growth factor beta 
superfamily (Schier, 2003; Shen, 2007). It plays a role in embryonic axes formation, 
induction of mesendoderm, patterning of nervous system and determining left and right 
asymmetry in vertebrates (Schier, 2003; Shen, 2007). Nodal has also been shown to 
maintain pluripotency of human embryonic stem cells (Vallier et al., 2004). Studies 
have shown that Nodal signalling reactivates in the neoplastic conditions (Topczewska 
et al., 2006). Several publications have presented the reappearance of Nodal in 
melanoma (Postovit et al., 2008; Topczewska et al., 2006), breast cancer (Postovit et 
al., 2008; Strizzi et al., 2008), gliomas (Lee et al., 2010), prostate cancer (Lawrence et 
al., 2011) and endometrial cancers (Papageorgiou et al., 2009). It is also evident that 
higher expression of nodal is specifically linked to more aggressive and invasive 
tumors like melanomas (Topczewska et al., 2006). Thus the expression of nodal in the 
BL melanoma cell line growing in PSCT, especially in the tumor cells migrating out 
and forming an invasive front while growing in the human embryonic environment is in 
line with the earlier findings on Nodal and it’s link with aggressiveness. What makes it 
more interesting is the expression of markers liked to dedifferentiation and absence of 
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markers related to differentiation, which suggests a more aggressive phenotype of 
melanoma cells in the PSCT.  
 
This study provided a proof of concept to study melanoma in the PSCT model. Since 
there are not many experimental in vivo melanoma models that are clinically relevant, 
the PSCT model could be potentially very useful tool to examine melanoma 
progression and it would also enable studies on species-specific tumor-host 
interactions.  
 
4.4 PAPER III 
Immature neural development in PSCT resembles the histology of neuroblastoma 
 
Aims of the study 
As described earlier, ectopic implantation of human pluripotent stem cells in mice 
results in differentiation defined as the formation of experimental teratoma. Notably, a 
prolonged immaturity of some neural components is regularly observed in benign 
PSCT rev by Cedervall et al. (Cedervall J, 2012). More specifically, immature neural 
areas in PSCT display histological resemblance with primitive neuroectodermal and 
neuroendocrine tumors. Similar histopathology, when appearing in patient samples for 
clinical diagnosis, is considered potentially malignant. However, in the PSCT model 
such histology is part of the chaotic but benign embryonic development (Paper I).  
 
This raised a prospect that the embryonic microenvironment in PSCT is particularly 
well suited for studies on neural childhood tumors. In Paper II we demonstrated how 
PSCT could provide growth support for a melanoma cell line. In Paper III, we tested 
for the support of neuroblastoma of childhood origin, with the principle of recuperating 
a closer developmental match between the injected tumor and the microenvironment. 
 
Here, we injected three human neuroblastoma (NB) cell lines (IMR-32, Kelly, and SK-
N-BE(2)), into human pluripotent stem cells induced teratoma (PSCT) in SCID/beige 
mice and the tumor growth was evaluated for histopathology and marker profiles. 
Proliferative tumor cells could readily be identified by FISH analysis and 
immunohistochemistry, and uniquely distinguishable from other human cells in the 
PSCT. The comparative analysis of all tumor cell lines was done with the xenografts of 
respective line. 
 
The main findings were as follows: 
 
Tropism 
 
All tumor injections resulted in the palpable tumor growth. All tumor lines showed a 
strict preference for integration, by always engrafting in areas compatible with 
undifferentiated embryonic loose mesenchymal stroma and never in areas compatible 
with other structures such as bone, muscles, gut, or other easily identifiable tissues in 
PSCT.  
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Noticeably, the undifferentiated stroma in the early embryo is formed by the embryonic 
loose mesenchyme. It is composed mainly of the mesodermal-derived cells, but 
includes also cells from other germ layers, e.g. ectodermal neural crest cells. It has a 
rich blood supply and includes also reticular fibers, creating a matrix. Cells of these 
embryonic connective tissues are typically spindle-, or star-shaped (stellate) and the 
amount of extracellular spaces between cells is relatively large. The extracellular matrix 
is filled with ground substance, which contains glycosaminoglycans, proteoglycans and 
glycoproteins. Similar appearance but with even more extracellular spaces and lesser 
reticular fibers is shown by mucoid connective tissue, which is a variant of embryonic 
connective tissue, present also in the umbilical cord (Wharton’s jelly). Hence the 
embryonic loose mesenchyme in PSCT can be best understood as a kind of generalized 
connective tissue, which can consist of all connective tissue cell types. 
 
In line with the above, the simplest explanation for the strong tropism of injected NB 
cells may be because the  “open” nature of loose mesenchyme more easily giving space 
to new cells compared to other more dense coherent tissues. Alternatively, and more 
intriguing, NB tumor cells could also be attracted towards the environmental cues 
supplied by the embryonic loose mesenchyme and which could be of advantage for NB 
cells. The chemical composition of ground substance consisting of all known 
components in cell signaling processes, are potentially ideally situated for cues 
supporting NB cells. This hypothesis is also supported by our previous observations, 
where only minor kinetic time deviations were observed between the HS181 PSCT and 
human early neural development (paper 1). In this context, it is interesting that the 
PSCT developmental stage of neural development and the time point used here for 
injecting NB tumor cells (PSCT day 45) overlaps with the timing of when adrenal 
sympatical progenitors position themselves in embryonic mesenchyme in human neural 
crest development (E25-35; (Betters et al., 2010)). NB is assumed to derive from 
precursor cells of neural crest that specifically differentiate into the sympaticoadrenal 
lineage. Thus, these findings indicate that day 45-60 mature HS181 PSCT may provide 
an advantageous and timely embryonic human neuroectodermal niche for in vivo 
studies on pediatric neuroblastoma.  
 
Expression of Nodal pathway 
 
Further support for the hypothesis discussed above, comes from studies of the 
embryonic morphogen Nodal and its inhibitor Lefty (for background see Paper II) Prior 
to this study, it was reported that aggressive human melanoma re-express an aberrant 
and unregulated embryonic Nodal signaling pathway associated with tumor cell 
plasticity (Postovit et al., 2008; Topczewska et al., 2006). Therefore, in current study it 
was determined whether the embryonic morphogen Nodal (dependently or 
independently with its co-receptor Cripto-1) was expressed on NB tumors in PSCT and 
it was found that the NB cells here faithfully mirrored the Nodal/Cripto-1/Lefty 
expression of neural crest cells in mammals (Shen, 2007).   
IMR-32 growing in PSCT or as xenorafts showed high expression of Nodal and Cripto 
but lefty was absent in PSCT and very low expression was shown in xenograft. 
 
 
 
  36 
Histology of tumor cells 
 
Tumor growth showed histological resemblance to that of clinical NB. In general, NB 
growth in both PSCT and as xenograft was undifferentiated or poorly differentiated 
having little or no interfoliating stroma or Schwann cell differentiation. Rosette 
formation, another trait of clinical NB, was commonly observed in tumors grafted in 
PSCT, but more rarely in the xenografts. Similar to clinical observations of NB, a 
considerably more heterogeneous growth pattern was found in the PSCT model 
compared to xenografts, as illustrated by organized and epitheloid-like growth in some 
areas and a dissociated and unstructured growth in other areas. A broader cellular 
diversity for tumors in PSCT was also suggested by the expression profiles, using 
markers for neurogenic (NSE), neuroendocrine (Synaptophysin and Chromogranin A), 
or melanocytic (Tyrosinase) phenotypes. Marker studies indicated differences between 
xenografts and PSCT, including tumor individual variations in phenotype. 
 
Induction of neovascularization upon injection of NB cell in PSCT 
 
Similar to the results in Paper II using a melanoma cell line, all NB tumors were well 
vascularized, with the blood vessels surrounding the tumor growth mainly of mouse 
origin but human origin of vessels was also detected by the positive expression of 
human CD31 cells. Detection of NB tumor nodules in close proximity of blood vessels 
was in line with the previously published results with various adult tumors (Paper II) 
and (Katz et al., 2009; Tzukerman et al., 2003; Tzukerman et al., 2006). In general the 
human vessels in PSCT were mainly located in the surrounding of the tumor growth. 
Interestingly, cells within SK-N-BE(2) xenograft tumors stained occasionally for 
human CD31, indicating a tumor cell differentiation into endothelial phenotype. In this 
way, a cell line-specific response to the microenvironment was observed. In general, 
SK-N-BE(2) tumors exhibited also the most aggressive phenotype. This NB line was 
originally derived from a bone marrow metastasis after several rounds of chemotherapy 
and radiation, and harbors a mutation in the p53 gene (ATCC).   
 
It would be expected for this more aggressive cell line to be less dependent, and thus 
less responsive, to influences from the tumor surroundings. Accordingly, SK-N-BE(2) 
did not exhibit the same level of variation between the different model systems. In 
contrast to Kelly and IMR-32 NB cells it tended to show a sporadic differentiation in 
the xenografts, which was not seen in PSCT. The presence of human CD31 positive 
cells could be interpreted as SK-N-BE(2) tumor cells differentiating into an  endothelial 
phenotype, a phenomenon denoted as “vascular mimicry”, previously described for 
tumors of various origins, including malignant melanoma (Maniotis et al., 1999), breast 
cancer (Postovit et al., 2008) and also NB (Pezzolo et al., 2007). 
 
Influence from the embryonic environment, versus species differences 
 
The differences observed in cellular diversity between the two models could be caused 
by either due to cues prompted from the embryonic environment vs. an “adult” 
environment or by species-specific cues induced by the PSCT cells i.e. human vs. 
mouse. To explore the influence of embryonic vs. species cues, the same tumors were 
also grown in the PSCT derived from mouse embryonic stem cells. The differences 
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observed in cellular diversity between xenografts and PSCT were influenced by both 
embryonic and species-specific cues. We found that the three NB cell lines varied in 
this respect. The IMR-32 line showed a similar growth pattern and histology in both the 
mouse and human PSCT models. Thus, growth pattern for IMR-32 correlated with the 
PSCT embryonic microenvironment and was not dependent on species. The Kelly and 
SK-N-BE(2) lines both showed a more differentiated tumor phenotype in the mouse 
PSCT as compared to the human PSCT indicating a species-specific influence on 
growth pattern. 
 
This study described NB growth in PSCT and recapitulates clinical observations. We 
suggest the PSCT model to be an important and complement to xenograft analysis for 
NB, and thus facilitating clinical translation. Considering the extremely poor prognosis 
of malevolent NB, further development of new models is of utmost importance.   
 
4.5 PAPER IV 
Studies on clinical tumor specimens in PSCT 
 
Aims of the study 
The findings in paper II and III suggested that the microenvironment in PSCT provide 
adequate support for growth of neuroectodermal tumors. To test for clinical relevance 
of these findings, we next evaluated the PSCT for in situ growth and progression of 
≤fresh or frozen/thawed tumor biopsy materials obtained from the surgery of childhood 
tumor patients at the Karolinska University Hospital.  
 
Engraftment into PSCT 
 
Tumor samples from the surgery of six children with; Supratentorial primitive 
neuroectodermal tumor (sPNET); Undifferentiated infratenturial tumor with 
sarcomatous features; Pilocytic astrocytoma of the brainstem; Classic 
medulloblastoma; Esthesio-NB and Neuroblastoma (NB), respectively, were 
transplanted into mature pluripotent stem cell-derived teratoma (PSCT). Each patient 
tumor specimen was transplanted into 2-6 PSCT and the tumors were allowed to 
engraft for 2-4 weeks. Engraftment was detected by XY chromosome specific FISH 
probes. H& E staining was used for morphological analysis and histopathological 
analysis was carried out using immunohistochemistry.  
 
Three out of six tumors showed engraftment; sPNET, Esthesio-NB and NB. Esthesio-
NB showed solitary cells or clusters of up to 14 cells, while NB and sPNET specimens 
gave rise to more protruding growth, reaching cohesive tumor areas. A detailed analysis 
was done on the latter two. Compared to the findings in paper III where all NB cell line 
give a palpable growth in both xenografts and PSCT systems, here it is a proof of the 
fact that primary tumor biopsies are harder to grow in vivo, likely due to their slow 
growth rate. There can be other explanations for the detection of only 50% tumor 
biopsies in PSCT. One limitation with the model was that tumor engraftments were 
limited to one month before the total size of the teratoma and tumor mass reached the 
maximum acceptable size, indicating that the model is more suited for faster growing 
tumors and some tumors analyzed in the study did not find time enough to engraft 
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considering their slower growth rate. Moreover, for technical reasons and time 
limitations we had to limit our search for tumor engraftment up to 100 sections, we can 
hope to find tumor engraftment if we cut the tissues deeper. This was possibly reflected 
in our findings with verified engraftment in three out of six cases, and cohesive growth 
was in fact only detected for the metastasizing NB and sPNET tumors. Notably, 
parallel xenograft-injections, of similar inoculation doses of tumor (approx. 1mm3), did 
not result in palpable tumor growth for any of the six tumors, after observations for up 
to four months. Therefore, selection of an appropriate and supportive model system is 
of crucial importance, not only for studying growth patterns but also for developing 
more effective anti-cancer therapies.  
 
Tropism 
 
A tissue tropism was observed for implanted clinical NB and sPNET specimens in 
PSCT, in line with our earlier findings on malignant melanoma cell line (paper II) and 
NB cell lines (paper III). Both NB and sPNET showed a specific tropism in that 
engraftment by NB cells were exclusively incorporating into areas of loose 
mesenchyme and the sPNET tumor was found in condensing neural ectoderm. Thus, 
sections from the PSCT model provided unique in vivo capturing of both progression 
and spread, using patient primary tumors. Neither tumor was detected in PSCT tissues 
identified as muscle, cartilage, gut, adrenal glands or epithelium of undefined origins. 
The finding on tissue tropism of the tumors studied in this thesis emphasizes the 
importance of establishing model systems that can better capture engraftment of 
neuroectodermal tumors compared to xenografts. This is also important to consider in 
pre-clinical testing of anti-cancer therapies where accurate prediction of efficacy in 
patients is essential. In oncology, the attrition rate in clinical trials following promising 
data in pre-clinical studies is disappointingly high, reaching levels of 80-95% 
(Hutchinson and Kirk, 2011). The background for this is multifactorial, however it 
would clearly be a benefit to have in vivo models better capturing the relevant 
neoplastic niche.  
Thus, PSCT model studied in this thesis provides a promising complement to the 
existing pre-clinical models. 
 
Vascularization 
 
A perivascular preference of engraftment was evident since tumor cells were regularly 
observed in the immediate proximity of vessels. This is also in line with our previous 
findings on Melanoma and NB cell lines. The PSCT microenvironment is well supplied 
by mouse vessels and human vessels are generally sparse and immature (Cedervall J, 
2012; Gerecht-Nir et al., 2004). However, others and we have observed enhanced 
vascularization in PSCT induced by the presence of tumor cells (Tzukerman et al., 
2003; Tzukerman et al., 2006).  Notably in the present study, both NB and sPNET were 
detected growing next to blood vessels, evidently taking advantage of a perivascular 
environment, previously suggested to influence tumorigenesis and/or aggressive 
behavior of neuroectodermal tumors (Axelson et al., 2005).  
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General histological findings 
 
The tumor cell morphology was similar to that of the patient original tumor and 
matched also to that of the neighboring immature PSCT tissues for both NB and 
sPNET. The NB and sPNET tumors were both very undifferentiated and aggressive 
tumors, and these qualities were maintained after changing the environment to PSCT. 
Both tumors showed an expression profile, before and after transfer, of beta-Catenin+, 
CD117+, CD56+, Vimentin+, E-cad-, CD117+. A mesenchymal phenotype was 
presented for both the sPNET and NB, in the original patient tumor as well as when 
growing in PSCT, indicated by a robust staining of Vimentin and a lack of E-Cadherin. 
 
However, while this profile was preserved, other changes in the molecular signature 
were indicated. The sPNET acquired the markers NSE (neurogenic) and Tyrosinase 
(melanocytic), indicating in this case a change to a more differentiated phenotype. The 
NB tumor on the other hand showed a loss of NFP and the neurogenic markers NSE, as 
well as a reduction or loss of the neuroendocrine markers CGA and Synaptophysin, 
suggesting a de-differentiation.  
 
Also, the NB tumor showed loss of CD44 in the PSCT. CD44 is a cell surface 
glycoprotein involved in cell-cell interaction, cell adhesion and migration. It is known 
to have a high expression in the progression of colon, breast and non-hodgkin 
lymphoma (Goodison et al., 1999). However, Favrot et al have studied the role of 
CD44 in 52 NB patients and concluded that unlike other tumors, the absence of CD44 
in NB indicated aggressive behavior (Favrot et al., 1993). Thus, the observed loss of 
also CD44 in PSCT could, together with the change of markers discussed above, have 
bearing on aggressiveness. Alternatively, in NB, cellular heterogeneity is a hallmark 
and NB is also known to vary in cytology, but not histology, possibly explaining some 
of the changes noted during growth in the PSCT (Favrot et al., 1986).  
 
This study established for the first time that childhood neuroectodermal tumors could 
engraft in a PSCT environment, showing also tropism with striking similarities to the 
tumor conditions in the young patients. The influence of surrounding tissues for 
promoting tumor growth and spread is well recognized, and there is strong consensus 
that the ability to invade host tissues and metastasize is dependent and mediated by 
several molecular routes that normally enable important physiological functions, such 
as morphogenesis, neurogenesis, and angiogenesis (Geho et al., 2005). 
 
In conclusion, the human PSCT microenvironment was found capable of supporting 
growth from patient childhood tumors of ectodermal origin, and providing striking 
similarities to the tumor conditions in the young patients. 
 
  
  40 
6 CONCLUSIONS 
 
Paper I 
 
Studies of early and late events in experimental human teratoma, generated from the 
pluripotent stem cell line HS181, demonstrated the occurrence of an embryonic process 
including increasingly chaotic embryonic tissues. Further, an emerging organoid 
development was observed exhibiting cellular differentiation with close resemblance to 
that of the developing human embryo.  
 
However, in line with earlier reports, a prolonged immaturity of some neural 
components was also observed. Similar histopathology when appearing in patient 
samples for clinical diagnosis is considered potentially malignant. Notably, in 
pluripotent stem cell induced teratoma (PSCT), such histology could be observed to be 
part of the chaotic but benign embryonic development. 
 
  
Papers II and III 
 
Based on the findings in Paper I, we observed predominant neural development in early 
PSCT and the histological resemblance of prolonged immature neural development in 
PCST to that of primitive neuroectodermal tumors, we hypothesized that the PSCT 
microenvironment could be well matched for studies of neuroectodermal tumors. 
 
This concept was in Paper II confirmed using a melanoma cell line, and in Paper III 
using three neuroblastoma cell lines. Both experimental situations resulted in tumor 
growth and morphology with strong resemblance to that of clinical tumors.  
Individual variations in molecular profiles for the three neuroblastoma cell lines were 
observed, providing additional information on the neuroblastoma tumor biology. 
 
Paper IV 
 
In this study we used, fresh or frozen, patient tumor materials and demonstrated for the 
first time that clinical childhood neuroectodermal tumors engraft into the PSCT 
environment. The patient tumor showed specific tissue tropism in their specific 
engraftment into developing mesenchymal and neuroectodermal tissues. 
 
Sections from the PSCT model demonstrated unique in vivo capturing of progression 
and micro invasion of the transplanted patient primary tumors - with striking 
similarities to the tumor conditions in the young patient. 
 
We conclude that the PSCT model delivers an in vivo environment allowing both NB 
and sPNET to maintain most of their original characteristics. This suggest that the 
PSCT environment is especially well suited for the assessment of childhood 
neuroectodermal tumors, and a strong complementary pre-clinical model for in vivo 
studies on childhood tumors.  
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7 FUTURE PROSPECTS 
 
• More tumors should be tested to investigate the potential of the system to 
support different tumor types originating from different cell types. The 
embryonic potential should be used to study more embryonic tumors in the 
same system. 
 
• Patient-specific iPSC giving rise to patient specific human environment will 
help understand the contribution of specific stroma to individual tumors.  
 
• Next, this opens up for possibilities to gauge anti-cancer drug exposure and 
pharmacodynamics in this human in vivo environment, a well-needed 
complement to current pre-clinical models in anti-cancer drug development. 
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